The HemOnc Pulse Live
Dr. Ryan Jacobs reviews the latest CLL data, highlighting time-limited regimens, BTK combos, and clinical trial updates.
In a podcast, experts explore chemo-free ALL therapies, CAR T breakthroughs, and the future of T-cell–targeted treatments.
Naval Daver, MD reviews new immunotherapy and targeted strategies transforming ALL treatment and outcomes.
Dr. Sanam Loghavi outlines genetic testing, MRD monitoring, and evolving strategies in newly diagnosed CLL.
Naval Daver, MD reviews new targeted therapies transforming AML treatment in both young and older patient groups.
A group of experts led by Naval Daver, MD discuss mutation loss, MRD dynamics, and transplant timing in evolving AML care.
Experts explore inflammation, immune escape, and diverging approaches in managing precursor myeloma.
Experts discuss quadruplet therapy, MRD, and evolving transplant decisions in newly diagnosed multiple myeloma.
Experts debate immune escape, inflammation, and early intervention in relapsed/refractory multiple myeloma.
Should interim PET scans still guide Hodgkin lymphoma treatment? Experts debate imaging, SUV changes, and biopsy use in HL.
Experts discuss T-cell lymphoma care, new therapies, transplant timing, and the role of NGS in treatment decisions.
Experts explore CAR T therapy challenges and the future of lymphoma care beyond CD19-targeted treatments.
Expert insights from a HemOnc Pulse Live! session offer a compelling look at where CML and MPN care is headed.
How have TKIs transformed CML survival and what’s next for treatment-free remission and deeper MPN responses?
Experts debate frontline CLL therapy—time-limited combos vs long-term BTKi—and the role of MRD in treatment decisions.
Ryan Jacobs, MD discusses 2025 CLL treatment advances, including BTK/BCL-2 combos, resistance, and time-defined strategies.
Experts discuss patient-centered approaches and novel therapies reshaping MF treatment in a roundtable.
Experts explore anemia therapies, JAK inhibitors, and transplant innovations shaping the promising future of MF care.
Experts discuss molecular insights into MF, highlighting mutations, risk assessment, and evolving therapeutic approaches.
Experts discuss current treatments and ongoing research in myelofibrosis, highlighting new therapies and clinical trials.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.